In Part 2 of this conversation on “Better Biopharma,” panelists from the Bioprocess Online Live event “Optimizing Process Development Through Upstream And Downstream Integration” continue their discussion about how upstream and downstream development teams can work together to accelerate timelines and reduce risk and bottlenecks in process development.

Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/

Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichiello/

Subscribe to our newsletters: https://www.bioprocessonline.com/user/edit/subscriptions

Tell us how we can improve. Take our 60-second survey: https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header

In this episode of “Better Biopharma,” panelists from the Bioprocess Online Live event “Optimizing Process Development Through Upstream And Downstream Integration” continue their conversation about how upstream and downstream development teams can work together to accelerate timelines and reduce risks and bottlenecks in process development.

Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/

Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichiello/

Subscribe to our newsletters: https://www.bioprocessonline.com/user/edit/subscriptions

Tell us how we can improve. Take our 60-second survey: https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header

In this episode of “Better Biopharma,” host Tyler Menichiello speaks with Michael McCullar, Ph.D., CEO at RegCell, a cell-therapy company developing regulatory T cell (Treg) therapies for autoimmune diseases. They discuss RegCell’s origins and its disease-agnostic approach to product development, as well as the ongoing efforts to improve the commercial viability of cell therapies by reducing manufacturing costs through automation and point-of-care models.

Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/

Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichiello/

Subscribe to our newsletters: https://www.bioprocessonline.com/user/edit/subscriptions

Tell us how we can improve. Take our 60-second survey: https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header

In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Nikolai Sopko, MD, Ph.D., chief operating officer, chief scientific officer, and director at PolarityBio, a biotech company developing SkinTE, an investigational autologous regenerative skin therapy for diabetic foot ulcers. The two discuss the challenges of scaling autologous therapy manufacturing, as well as the success PolarityBio has found in doing so through its parallel processing approach.

Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/

Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichiello/

Subscribe to our newsletters: https://www.bioprocessonline.com/user/edit/subscriptions

Tell us how we can improve. Take our 60-second survey: https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header

In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Richard Moroney, Ph.D., managing director at Stat Consulting. Moroney shares his thoughts on how organizations should think about and approach process control. His philosophy is one of continuous process improvement, as he believes there is "no ceiling" on quality control.

Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/

Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichiello/

Subscribe to our newsletters: https://www.bioprocessonline.com/user/edit/subscriptions

Tell us how we can improve. Take our 60-second survey: https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header

In this episode of “Better Biopharma,” host Tyler Menichiello is joined by FibroBiologics’ CEO and founder, Pete O’Heeron, and chief scientific officer, Hamid Khoja, Ph.D. They discuss the powerful but often overlooked fibroblast, a type of connective-tissue cell that has tremendous therapeutic potential, according to O’Heeron and Khoja. They explain the company’s mission to realize this therapeutic potential and make fibroblasts a mainstay in the cell therapy space, rivaling the prominence of stem cells.

Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/

Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichiello/

Subscribe to our newsletters: https://www.bioprocessonline.com/user/edit/subscriptions

Tell us how we can improve. Take our 60-second survey: https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header

In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Eric Doerr, a drug substance technical lead in the manufacturing science and technology (MSAT) group at Sanofi. The two discuss how the industry can support the next generation of biomanufacturing workers in North America, comparing incentives and initiatives in both the U.S. and Canada, where Doerr is based. Doerr also shares his thoughts on the need to proactively train workers in using AI to ensure that it serves as an enabling tool, rather than a disruptive force.

Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/

Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichiello/

Subscribe to our newsletters: https://www.bioprocessonline.com/user/edit/subscriptions

Tell us how we can improve. Take our 60-second survey: https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header

In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Herman Bozenhardt, a consultant and industry veteran who has spent decades advancing the fields of biopharmaceutical manufacturing, engineering, and regulatory compliance. Bozenhardt outlines his concerns with the current outsourcing environment, noting a rising rate of noncompliance driven by poor facility maintenance and a shortage of reliable workers. He offers advice to sponsor companies working with CDMOs to help ensure their assets don’t fall victim to poor partnerships and operational mismanagement.

Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/

Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichiello/

Subscribe to our newsletters: https://www.bioprocessonline.com/user/edit/subscriptions

Tell us how we can improve. Take our 60-second survey: https://docs.google.com/forms/d/e/1FAIpQLSfZGJluCmEhm1MBQvcm7_gtBEXuTx5v42LJ1mx9bCUKo8fwfg/viewform?usp=header